2018 Safety Side effects 
Pharmaceutical Technology
MAY 25, 2023
The biobank will work in parallel with the MHRA’s Yellow Card website, which is used for reporting adverse events and side effects caused by medicines and medical devices, per the 25 May announcement. According to the press release, the MHRA will be the first drug safety regulator in the world to pilot such a biobank.
pharmaphorum
SEPTEMBER 16, 2022
The week 16 data of lebrikizumab […] points towards a drug with robust efficacy with hardly any safety trade-offs. Minor side effects to long-term maintenance balance. Any clinical study seeks to achieve maximum results efficacy with minimal occurrence of side effects. However, side effects do happen.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
European Pharmaceutical Review
JUNE 12, 2024
Since 2018, biotech company Mikrobiomik has been researching, development and producing innovative biological medicines based on the human microbiome. Donor of stools for MBK-01 were screened for pathogens and viruses to ensure safety. Safety and quality of life of the patients participating in the study were also assessed.
Pharmaceutical Technology
JANUARY 22, 2023
In 2022, the FDA approved only 37 new medicines, an underwhelming number compared to 98 in 2018. However, while only around 34% of the approvals in 2018 were for orphan drugs, 54% new approvals in 2022 were for drugs to treat rare diseases. In clinical trials, the drug showed a 3.8-point point improvement (unadjusted means) and a 3.2-point
European Pharmaceutical Review
AUGUST 14, 2023
This data, together with a favourable safety profile, make C21 a potential game-changer for IPF patients, particularly those who are currently not treated due to the side effects of the available drugs, according to Dalsgaard.
Pharmaceutical Technology
JANUARY 25, 2023
By selectively degrading these proteins, PROTACs have the potential to effectively treat a range of diseases with potentially fewer side effects compared to traditional approaches. Syngene is setting up the predictive models and new platforms to overcome these challenges.”
European Pharmaceutical Review
JULY 5, 2022
There is an urgent need for more effective chemotherapy treatments with less severe toxicity and side effects. Irinotecan – also known by the brand name Campto/Camptosar ® (Pfizer Ltd.) – has proven to be an effective chemotherapy agent against several types of gastrointestinal cancer. About the author. Oncotarget.
Expert insights. Personalized for you.
52 
Let's personalize your content